FHIP1B

Summary

FHIP1B (FHF complex subunit HOOK interacting protein 1B, HGNC:25378) is a protein-coding gene on chromosome 11p15.4, encoding FHF complex subunit HOOK-interacting protein 1B (Q8N612). Component of the FTS/Hook/FHIP complex (FHF complex).

The protein encoded by this gene is part of the FTS/Hook/FHIP (FHF) complex, which can interact with members of the homotypic vesicular protein sorting (HOPS) complex. This interaction suggests that the encoded protein is involved in vesicle trafficking.

Source: NCBI Gene 84067 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 200 total
• MANE Select transcript: NM_001098794

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25378
Approved symbol	FHIP1B
Name	FHF complex subunit HOOK interacting protein 1B
Location	11p15.4
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22665, KIAA1759, DKFZP566M1046, FHIP
Ensembl gene	ENSG00000051009
Ensembl biotype	protein_coding
OMIM	620229
Entrez	84067

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 10 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000265978, ENST00000449352, ENST00000524416, ENST00000529360, ENST00000532797, ENST00000868132, ENST00000868133, ENST00000937932, ENST00000937933, ENST00000955061, ENST00000955062, ENST00000955063

RefSeq mRNA: 2 — MANE Select: NM_001098794 NM_001098794, NM_032127

CCDS: CCDS44530, CCDS7760

Canonical transcript exons

ENST00000449352 — 12 exons

Exon	Start	End
ENSE00000903295	6223080	6223238
ENSE00000903296	6222811	6222897
ENSE00000903297	6222442	6222609
ENSE00000903298	6218971	6219050
ENSE00000903300	6217371	6218150
ENSE00000903301	6214733	6214911
ENSE00001685162	6223610	6224248
ENSE00001802120	6218600	6218763
ENSE00002164838	6234544	6234636
ENSE00002731133	6224379	6224707
ENSE00003508742	6214411	6214573
ENSE00003902584	6211345	6211867

Expression profiles

Bgee: expression breadth ubiquitous, 246 present calls, max score 97.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.0412 / max 133.8733, expressed in 1790 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
118394	11.6964	1790
118395	0.3449	158

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	97.72	gold quality
mucosa of transverse colon	UBERON:0004991	97.33	gold quality
right uterine tube	UBERON:0001302	97.21	gold quality
transverse colon	UBERON:0001157	96.71	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.19	gold quality
right testis	UBERON:0004534	96.16	gold quality
left testis	UBERON:0004533	95.96	gold quality
granulocyte	CL:0000094	95.81	gold quality
rectum	UBERON:0001052	95.58	gold quality
right lobe of thyroid gland	UBERON:0001119	95.56	gold quality
left lobe of thyroid gland	UBERON:0001120	95.45	gold quality
right lobe of liver	UBERON:0001114	95.28	gold quality
body of pancreas	UBERON:0001150	95.17	gold quality
small intestine	UBERON:0002108	95.05	gold quality
thyroid gland	UBERON:0002046	94.71	gold quality
body of stomach	UBERON:0001161	94.43	gold quality
right coronary artery	UBERON:0001625	94.22	gold quality
skin of abdomen	UBERON:0001416	94.10	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.94	gold quality
body of uterus	UBERON:0009853	93.80	gold quality
testis	UBERON:0000473	93.74	gold quality
pancreatic ductal cell	CL:0002079	93.69	gold quality
colon	UBERON:0001155	93.62	gold quality
intestine	UBERON:0000160	93.57	gold quality
tibial nerve	UBERON:0001323	93.57	gold quality
adenohypophysis	UBERON:0002196	93.57	gold quality
endocervix	UBERON:0000458	93.53	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.50	gold quality
mucosa of stomach	UBERON:0001199	93.48	gold quality
gall bladder	UBERON:0002110	93.43	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-3929	yes	109.44
E-ANND-3	yes	5.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

47 targeting FHIP1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-12136	99.98	72.81	5713
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4446-5P	99.72	69.19	2544

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	fhip1b	ENSDARG00000078188
mus_musculus	Fhip1b	ENSMUSG00000044465
rattus_norvegicus	Fhip1b	ENSRNOG00000017408
drosophila_melanogaster	CG3558	FBGN0025681
caenorhabditis_elegans		WBGENE00015485

Paralogs (3): FHIP2A (ENSG00000151553), FHIP2B (ENSG00000158863), FHIP1A (ENSG00000164142)

Protein

Protein identifiers

FHF complex subunit HOOK-interacting protein 1B — Q8N612 (reviewed: Q8N612)

Alternative names: FTS- and Hook-interacting protein

All UniProt accessions (2): E9PJK5, Q8N612

UniProt curated annotations — full annotation on UniProt →

Function. Component of the FTS/Hook/FHIP complex (FHF complex). The FHF complex may function to promote vesicle trafficking and/or fusion via the homotypic vesicular protein sorting complex (the HOPS complex). FHF complex promotes the distribution of AP-4 complex to the perinuclear area of the cell.

Subunit / interactions. Component of the FTS/Hook/FHIP complex (FHF complex), composed of AKTIP/FTS, FHIP1B, and one or more members of the Hook family of proteins HOOK1, HOOK2, and HOOK3. The FHF complex associates with the homotypic vesicular sorting complex (the HOPS complex).

Similarity. Belongs to the FHIP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8N612-1	1	yes
Q8N612-2	2
Q8N612-3	3

RefSeq proteins (2): NP_001092264, NP_115503 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019384	FHIP	Family
IPR045668	FHIP_KELAA_motif	Conserved_site
IPR045669	FHIP_C	Domain

Pfam: PF10257, PF19311, PF19314

UniProt features (68 total): helix 35, modified residue 7, turn 7, splice variant 4, sequence variant 4, sequence conflict 4, region of interest 2, strand 2, compositionally biased region 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8QAT	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N612-F1	69.52	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 859, 897, 467, 510, 523, 529, 533

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (6): endosome organization (GO:0007032), lysosome organization (GO:0007040), endosome to lysosome transport (GO:0008333), protein transport (GO:0015031), early endosome to late endosome transport (GO:0045022), protein localization to perinuclear region of cytoplasm (GO:1905719)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): FHF complex (GO:0070695)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
cytoplasm	2
endomembrane system organization	1
vesicle organization	1
lytic vacuole organization	1
lysosomal transport	1
intercellular transport	1
vesicle-mediated transport	1
transport	1
establishment of protein localization	1
vesicle-mediated transport between endosomal compartments	1
binding	1
protein-containing complex	1

Protein interactions and networks

STRING

990 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FHIP1B	AKTIP	Q9H8T0	870
FHIP1B	HOOK3	Q86VS8	798
FHIP1B	HOOK1	Q9UJC3	730
FHIP1B	HOOK2	Q96ED9	664
FHIP1B	VPS18	Q9P253	576
FHIP1B	FAM241B	Q96D05	446
FHIP1B	FERRY3	Q9NQ89	437
FHIP1B	LRGUK	Q96M69	436
FHIP1B	BICDL2	A1A5D9	424
FHIP1B	FHIP2B	Q86V87	403
FHIP1B	KIF1C	O43896	390
FHIP1B	FHIP2A	Q5W0V3	383
FHIP1B	CCDC141	Q6ZP82	370
FHIP1B	RUSC2	Q8N2Y8	369
FHIP1B	BLTP3A	Q6BDS2	356

IntAct

33 interactions, top by confidence:

A	B	Type	Score
HOOK3	FHIP1A	psi-mi:“MI:0914”(association)	0.710
FHIP1B	REEP6	psi-mi:“MI:0915”(physical association)	0.670
REEP6	FHIP1B	psi-mi:“MI:0915”(physical association)	0.670
FHIP1B	RAB5B	psi-mi:“MI:0407”(direct interaction)	0.600
FHIP1B	RAB5B	psi-mi:“MI:0915”(physical association)	0.600
FHIP1B	RAB5B	psi-mi:“MI:0403”(colocalization)	0.600
AGTRAP	FHIP1B	psi-mi:“MI:0915”(physical association)	0.560
FHIP1B	YPT53	psi-mi:“MI:0915”(physical association)	0.560
ANKRD22	ESYT2	psi-mi:“MI:0914”(association)	0.530
AP4B1	FHIP1B	psi-mi:“MI:0914”(association)	0.480
HOOK1	FHIP2B	psi-mi:“MI:0914”(association)	0.420
HOOK3	FHIP2B	psi-mi:“MI:0914”(association)	0.420
FHIP1B	RPL7A	psi-mi:“MI:0915”(physical association)	0.400
RTN1	FHIP1B	psi-mi:“MI:0915”(physical association)	0.370
RABAC1	FHIP1B	psi-mi:“MI:0915”(physical association)	0.370
RTN3	FHIP1B	psi-mi:“MI:0915”(physical association)	0.370
AP4E1	HOOK3	psi-mi:“MI:0914”(association)	0.350
FHIP1B	HOOK2	psi-mi:“MI:0914”(association)	0.350
GPR17	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TNFSF13B	TNPO2	psi-mi:“MI:0914”(association)	0.350
AKTIP	PGGT1B	psi-mi:“MI:0914”(association)	0.350
AKTIP	ALDH1A2	psi-mi:“MI:0914”(association)	0.350
HOOK3	ETHE1	psi-mi:“MI:0914”(association)	0.350
FHIP1A	ILVBL	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (72): FAM160A2 (Two-hybrid), REEP6 (Two-hybrid), FAM160A2 (Affinity Capture-MS), FAM160A2 (Affinity Capture-MS), FAM160A2 (Two-hybrid), FAM160A2 (Two-hybrid), FAM160A2 (Two-hybrid), REEP6 (Two-hybrid), FAM160A2 (Synthetic Lethality), FAM160A2 (Affinity Capture-MS), FAM160A2 (Affinity Capture-MS), FAM160A2 (Affinity Capture-MS), FAM160A2 (Two-hybrid), FAM160A2 (Proximity Label-MS), FAM160A2 (Proximity Label-MS)

ESM2 similar proteins: A5PJM7, A6QL63, A7YY62, A7Z026, B2RYF1, E9PV86, O35393, O54951, O70141, O75864, P42229, P42230, P42231, P51692, Q15768, Q29RM4, Q3SZB3, Q3U2I3, Q3UFK8, Q5R5M3, Q5R8V2, Q5U2R3, Q5ZJA4, Q5ZJB7, Q66H54, Q6DN14, Q6GQW0, Q6IA17, Q6ZN54, Q6ZUT9, Q7Z6G3, Q7Z6J6, Q86VR8, Q8BKR5, Q8N5X7, Q8N612, Q8NBT3, Q8TBP0, Q8TF64, Q8WXS5

Diamond homologs: A7S6A1, A7YY62, B0X755, B3MLI0, B3NAN9, B4G8N3, B4JQY3, B4KJS5, B4LQW4, B4MTY2, B4NXB9, B5DI68, Q05DH4, Q17AI4, Q3U2I3, Q505K2, Q5R8V2, Q66H54, Q7PZ36, Q8N612, Q9VQK0, A8XW52, B0V207, Q11187, A8P7J8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 28 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
endosome organization	5	85.1×	2e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

200 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	172
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1651 predictions. Top by Δscore:

Variant	Effect	Δscore
11:6217759:C:A	donor_gain	1.0000
11:6218149:ACCTG:A	acceptor_loss	1.0000
11:6218151:C:CA	acceptor_loss	1.0000
11:6218577:C:CA	donor_gain	1.0000
11:6218972:TGAGA:T	donor_gain	1.0000
11:6219046:CAGAG:C	acceptor_gain	1.0000
11:6219051:C:CC	acceptor_gain	1.0000
11:6222437:CATA:C	donor_loss	1.0000
11:6222439:TACC:T	donor_loss	1.0000
11:6222440:A:AC	donor_gain	1.0000
11:6222440:A:T	donor_loss	1.0000
11:6222440:AC:A	donor_gain	1.0000
11:6222441:C:CC	donor_gain	1.0000
11:6222441:CC:C	donor_gain	1.0000
11:6222451:A:AC	donor_gain	1.0000
11:6222452:C:CC	donor_gain	1.0000
11:6222605:GAGGT:G	acceptor_gain	1.0000
11:6222606:AGGT:A	acceptor_gain	1.0000
11:6222607:GGT:G	acceptor_gain	1.0000
11:6222608:GT:G	acceptor_gain	1.0000
11:6222608:GTC:G	acceptor_loss	1.0000
11:6222609:TCT:T	acceptor_loss	1.0000
11:6222610:C:CC	acceptor_gain	1.0000
11:6222610:C:CG	acceptor_loss	1.0000
11:6222611:T:G	acceptor_loss	1.0000
11:6222613:C:CT	acceptor_gain	1.0000
11:6222615:C:CT	acceptor_gain	1.0000
11:6222616:A:T	acceptor_gain	1.0000
11:6222906:G:GC	acceptor_gain	1.0000
11:6222910:C:CT	acceptor_gain	1.0000

AlphaMissense

6173 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:6217872:A:G	W572R	1.000
11:6217872:A:T	W572R	1.000
11:6218736:C:A	M433I	1.000
11:6218736:C:G	M433I	1.000
11:6218736:C:T	M433I	1.000
11:6222842:A:G	L331P	1.000
11:6222844:G:C	F330L	1.000
11:6222844:G:T	F330L	1.000
11:6222845:A:G	F330S	1.000
11:6222846:A:G	F330L	1.000
11:6211621:A:G	L935P	0.999
11:6211624:A:G	F934S	0.999
11:6211651:A:T	V925D	0.999
11:6214749:A:T	V793D	0.999
11:6214764:A:T	V788D	0.999
11:6214779:A:G	L783P	0.999
11:6214782:A:G	L782P	0.999
11:6214815:G:T	A771D	0.999
11:6214818:A:G	L770P	0.999
11:6214839:A:G	L763P	0.999
11:6214847:G:C	N760K	0.999
11:6214847:G:T	N760K	0.999
11:6214881:A:G	L749P	0.999
11:6214911:C:T	G739D	0.999
11:6217371:C:G	G739R	0.999
11:6217870:C:A	W572C	0.999
11:6217870:C:G	W572C	0.999
11:6218662:G:T	P458Q	0.999
11:6218677:A:G	F453S	0.999
11:6218737:A:G	M433T	0.999

dbSNP variants (sampled 300 via entrez): RS1000024554 (11:6219523 G>A), RS1000324883 (11:6225223 T>C), RS1000366143 (11:6231463 T>C), RS1000438109 (11:6219228 C>G), RS1000456245 (11:6215774 G>C), RS1000780905 (11:6224912 T>G), RS1000996707 (11:6220533 C>A), RS1001200425 (11:6219884 G>A), RS1001265647 (11:6226047 T>C), RS1001308903 (11:6226573 G>T), RS1001336199 (11:6212772 A>G), RS1001342580 (11:6214700 C>A,G), RS1001455087 (11:6215214 A>C), RS1001483148 (11:6220173 A>C), RS1001705024 (11:6232039 A>G)

Disease associations

OMIM: gene MIM:620229 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST010725_20	Malaria	4.000000e-69
GCST010725_33	Malaria	2.000000e-67
GCST010725_51	Malaria	1.000000e-55

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
pirinixic acid	increases activity, affects binding, decreases expression	1
bisphenol A	affects cotreatment, decreases expression	1
trichostatin A	affects expression	1
sodium arsenite	increases expression	1
abrine	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	affects phosphorylation	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, decreases expression	1
Ozone	affects expression, increases abundance	1
Smoke	decreases expression	1
Tretinoin	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Cyclosporine	increases expression	1
Cadmium Chloride	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer